US 12,129,290 B2
Monoclonal antibodies, compositions and methods for detecting complement factor D
William Jason Cummings, Bellevue, WA (US); Jeremy A. Freeman, Shoreline, WA (US); Yi Li, Seattle, WA (US); Kathleen A. Shaffer, Rosharon, TX (US); and Munehisa Yabuki, Seattle, WA (US)
Assigned to Omeros Corporation, Seattle, WA (US)
Filed by Omeros Corporation, Seattle, WA (US)
Filed on Aug. 17, 2021, as Appl. No. 17/404,323.
Claims priority of provisional application 63/197,833, filed on Jun. 7, 2021.
Claims priority of provisional application 63/066,942, filed on Aug. 18, 2020.
Claims priority of provisional application 63/066,948, filed on Aug. 18, 2020.
Prior Publication US 2022/0056117 A1, Feb. 24, 2022
Int. Cl. C07K 16/18 (2006.01); G01N 33/573 (2006.01)
CPC C07K 16/18 (2013.01) [G01N 33/573 (2013.01); C07K 2317/34 (2013.01); C07K 2317/92 (2013.01); G01N 2333/96433 (2013.01)] 33 Claims
OG exemplary drawing
 
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to an epitope on the activation (“Pro”) peptide of human Factor D, wherein the isolated antibody or antigen-binding fragment thereof comprises a binding domain comprising the following six CDRs:
(i): (a) an HC-CDR1 comprising the amino acid sequence XYWMS (SEQ ID NO:201), wherein X at position 1 is N, S or T; (b) an HC-CDR2 comprising the amino acid sequence EIRLKSXNYAXXYXESVKG (SEQ ID NO:202), wherein: X at position 7 is D or E, X at position 11 is T or A, X at position 12 is H or Y and X at position 14 is A or T; (c) an HC-CDR3 comprising the amino acid sequence AWFAX (SEQ ID NO:203), wherein X at position 5 is S, Y or N; (d) a LC-CDR1 comprising the amino acid sequence XSSQXLLYSXDQKNYLA (SEQ ID NO:204), wherein X at position 1 is M or K, X at position 5 is S or N, and X at position 10 is K or R; (e) a LC-CDR2 comprising the amino acid sequence WASTRES (SEQ ID NO: 178); and (f) a LC-CDR3 comprising the amino acid sequence LQYYXYPYT (SEQ ID NO:205), wherein X at position 5 is T or S; or
(ii): (a) a CDR-H1 comprising SEQ ID NO:167, (b) a CDR-H2 comprising SEQ ID NO:169 or SEQ ID NO: 173; (c) a CDR-H3 comprising SEQ ID NO:171 or SEQ ID NO: 174; (d) a CDR-L1 comprising SEQ ID NO: 194, (e) a CDR-L2 comprising SEQ ID NO:196 or SEQ ID NO: 199 and (f) a CDR-L3 comprising SEQ ID NO: 198 or SEQ ID NO:200.